1. India Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Aspira Pathlab & Diagnostics Ltd.

Aspira Pathlab & Diagnostics Ltd.

BBSE:ASPIRA
123.45
INR
+3.10
(+2.58%)
-0.45EPS
1.34BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
1.46
8.39
10.92
9.82
15.97
18.99
14.05
12.83
21.37
24.27
25.72
Basic EPS, GAAP
0.03
0.04
0.05
-5.25
-10.75
-7.41
-4.95
1.45
4.33
-0.09
-2.6
2.01
0.05
-0.45
Free Cash Flow per Basic Share
-0.05
0.01
-0.78
-16.2
-11.18
-5.57
-2.23
5.65
1.38
-0.14
0.77
1.49
0.73
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.21
6.95
7.01
11.39
0.64
0.32
-1.21
3.29
7.64
7.6
5.07
7.08
7.09
- -
Tangible Book Value per Share
1.21
6.95
7.01
9.28
-1.38
-2.99
-4.08
0.57
4.96
4.98
2.47
4.49
3.87
- -
Basic Weighted Avg Shares
5
5
5
5
5
7
9
10
10
10
10
10
10
10
Sales/Revenue/Turnover
- -
- -
- -
8
44
76
84
152
195
145
132
220
250
259
Operating Margin (%)
- -
- -
- -
-362.04
-114.53
-57.76
-41.37
13.62
25.93
0.08
-20.47
9.43
-0.09
-2.29
Depreciation Expense
- -
- -
- -
2
11
12
17
14
16
16
15
15
15
16
Net Income, GAAP
- -
- -
- -
-27
-56
-52
-42
14
45
-1
-27
21
1
-5
Effective Tax Rate (%)
30.9
64.15
25.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-359.09
-128.1
-67.86
-50.38
9.08
22.82
-0.61
-20.24
9.42
0.21
-1.75
Working Capital
6
36
31
-18
2
-19
-18
19
54
43
23
30
15
- -
LT Debt
- -
- -
- -
32
105
42
45
5
24
17
10
12
11
- -
Total Equity
6
36
36
59
3
52
38
83
128
128
101
122
122
- -
Return on Invested Capital (%)
-1.74
0.65
-2.7
- -
- -
- -
- -
19.11
37.59
- -
- -
16.29
-0.56
- -
Return on Capital (%)
2.55
1.1
1.26
- -
- -
- -
- -
20.06
37.42
- -
- -
18.25
2.71
- -
Return on Common Equity (%)
2.55
1.1
0.76
-57.04
-178.61
-1,737.89
- -
- -
79.32
-1.13
-41
33.16
0.7
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
9
- -
LT Borrowings
- -
14
- -
LT Finance Leases
- -
11
- -
Preferred Equity and Hybrid Capital
- -
49
- -
Shares Outstanding
10
10
10
Market Capitalization
681
575
1,338

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
46
- -
Cash, Cash Equivalents & STI
- -
17
- -
Accounts Receivable, Net
- -
17
- -
Inventories
- -
7
- -
Total Current Liabilities
- -
31
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
9
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
156.44%
10.73%
0.12%
Free Cash Flow
70.71%
-154.73%
-50.73%
Net Income, GAAP
-732.28%
551.69%
-97.52%
Sales/Revenue/Turnover
- -
14.8%
13.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
46
62
54
58
220
2026
52
81
51
65
250
2027
62
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.05
0.96
0.37
0.7
2.01
2026
0.46
1.78
-1.52
-0.67
0.05
2027
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nikunj Velji Mange
Full Time Employees
168
Sector
Health services
Industry
Medical/Nursing services
Address
6 & 7, Bhaveshwar Arcade Mumbai MA India 400086
IPO Date
Dec 5, 2017
Website
aspiradiagnostics.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Aspira Pathlab & Diagnostics Limited is a prominent entity in the diagnostic services sector, operating a vast network of diagnostic centers and laboratories across India. The company offers a comprehensive array of medical diagnostic and testing services, encompassing sophisticated pathological investigations such as bio-chemistry, hematology, histopathology, microbiology, immune-chemistry, immunology, virology, and cytology. Beyond pathology, Aspira also provides radiological examinations including X-rays and ultrasound sonography, alongside various cardiology services. With a focus on both individual patient care and corporate wellness, Aspira crafts preventive health packages for diverse age groups, conducts on-site and off-site employee health evaluations, offers industry-specific rapid screening, and manages secure employee health data. Established in 1973, the company prides itself on technological automation and IT integration, aimed at reducing human error and ensuring precise sample tracking. Aspira has expanded its reach significantly, now operating over 600 centers nationwide, with 91 new locations added in the fiscal year 2024-25 alone. Recent financial results indicate a strong performance, with the company reporting a profit of Rs. 2.07 crores for FY 2024-25, a notable improvement from a prior year's loss. Furthermore, for the second quarter ending September 30, 2025, Aspira recorded increased sales of INR 80.93 million and a net income of INR 18.35 million. An open offer was announced on September 26, 2025, by a consortium of acquirers to purchase a 26% stake in the company. Headquartered in Navi Mumbai, India, Aspira reinforces its patient-centric approach through services like home sample collection and its AspiraHealth mobile application, which facilitates appointment booking and access to test results.